Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Sanofi - Aventis Groupe

< Previous 1 2 3 4 5 Next >
Press Release: Sanofi delivers first medicines from Global Health Unit’s Impact brand portfolio
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: TZIELD® Phase 3 data presented at ISPAD shows potential to slow the progression of Stage 3 type 1 diabetes in newly diagnosed children and adolescents; full data simultaneously published in The NEJM
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Late-breaking amlitelimab Phase 2b data presented at EADV show potential best-in-class profile in atopic dermatitis
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Sanofi and Teva announce exclusive collaboration to deliver inflammatory bowel disease treatment
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Sanofi announces agreement for potential first-in-class vaccine against extraintestinal pathogenic E. coli
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Once-weekly ALTUVIIIO® approved in Japan as a new class of factor VIII therapy for hemophilia A
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Sanofi supporting vulnerable communities as part of commitment to social impact and fight against climate change
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Sanofi announces changes to its Executive Committee
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: U.S. CDC Advisory Committee unanimously recommends routine use of Beyfortus™ (nirsevimab-alip) to protect infants against RSV disease
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press release: Online availability of Sanofi’s half-year financial report for 2023
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Sanofi to acquire Qunol®, a fast-growing U.S. brand in the healthy aging segment
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Solid Q2 performance and strong pipeline momentum, Full-year 2023 business EPS guidance raised
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: FDA approves Beyfortus™ (nirsevimab-alip) to protect infants against RSV disease
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Vaccines R&D pipeline raises the bar in RSV, influenza, meningitis, and pneumococcal disease
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Positive topline Phase 2b data in atopic dermatitis support amlitelimab as a potential first and best-in-class novel investigational anti-OX40-ligand monoclonal antibody
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: ALTUVIIIO late-breaking data at ISTH demonstrates highly effective bleed protection in children with severe hemophilia A with once-weekly dosing
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Availability of the Q2 2023 Memorandum for modelling purposes
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Sanofi prevails in Zantac arbitration initiated by Boehringer Ingelheim
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Sanofi “all in” on artificial intelligence and data science to speed breakthroughs for patients
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: FDA Advisory Committee unanimously recommends nirsevimab as first immunization against RSV disease for all infants
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Sanofi launches 2023 global Employee Stock Purchase Plan
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Positive Phase 2 data of novel investigational anti-CD40L antibody frexalimab show significantly reduced disease activity in relapsing multiple sclerosis
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Annual General Meeting of May 25, 2023 – Frédéric Oudéa new Chairman of the Board of Directors
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Dupixent® (dupilumab) late-breaking Phase 3 COPD results presented at ATS and simultaneously published in the New England Journal of Medicine
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Nirsevimab delivers 83% reduction in RSV infant hospitalizations in a real-world clinical trial setting
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Sanofi completes acquisition of Provention Bio, Inc.
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Strong Q1 growth driven by Specialty Care, Vaccines and CHC
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Hart-Scott-Rodino waiting period expires for Sanofi’s acquisition of Provention Bio, Inc.
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Nirsevimab: Sanofi, AstraZeneca and Sobi simplify contractual agreements
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Sanofi announces withdrawal and refiling of Premerger Notification and Report Form under the HSR Act and extension of tender offer to acquire Provention Bio, Inc.
From Sanofi - Aventis Groupe
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.